Read by QxMD icon Read

Prostate cancer and diabetes

shared collection
22 papers 25 to 100 followers
By Axel Cayetano Urology Resident
Jean de la Rosette, M Pilar Laguna
No abstract text is available yet for this article.
July 25, 2015: Lancet
Emil Kheterpal, Jesse D Sammon, Mireya Diaz, Akshay Bhandari, Quoc-Dien Trinh, Naveen Pokala, Pranav Sharma, Mani Menon, Piyush K Agarwal
OBJECTIVE: The prevalence of metabolic syndrome has been increasing worldwide, however its association with prostate cancer (CaP) is unclear. We reviewed patients undergoing robot assisted radical prostatectomy (RARP) to evaluate if those with metabolic syndrome had more aggressive disease. MATERIALS AND METHODS: A prospective database of patients undergoing RARP between January 2005 and December 2008 (n = 2756) was queried for components of metabolic syndrome (BMI ≥ 30 and ≥ 2 of the following: hypertension, diabetes or elevated blood glucose, and dyslipidemia; n = 357)...
October 2013: Urologic Oncology
Hua Xu, Hao-wen Jiang, Guan-xiong Ding, Hu Zhang, Li-min Zhang, Shan-hua Mao, Qiang Ding
AIM: Prior studies have reported that diabetes mellitus might reduce the overall prostate cancer risk. We examined this association by conducting a detailed meta-analysis of the studies published in peer-reviewed literature on the association between diabetes mellitus and prostate cancer risk of different stage or grade. METHODS: A comprehensive search for articles of MEDLINE and EMBASE databases and bibliographies of retrieved articles published up to October 23, 2012 was performed...
March 2013: Diabetes Research and Clinical Practice
X-X He, S M Tu, M-H Lee, S-C J Yeung
BACKGROUND: The association between antidiabetic medications and the prognosis of human prostate cancer has not been explored. This study examined the impact of these drugs on the outcomes of diabetic patients with prostate cancer to provide a basis for diabetes management strategy in these patients. PATIENTS AND METHODS: Records of consecutive prostate cancer patients with coexisting diabetes mellitus type 2 who were treated at the study institution between 15 July 1999 and 31 December 2008 were reviewed...
December 2011: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Brandon L Pierce
A large body of epidemiologic evidence provides strong support for the notion that type-2 diabetics are at decreased risk for prostate cancer. In this review article, we summarize the epidemiologic literature that explores the role of diabetes mellitus and related biomarkers in prostate cancer risk and detection, in order to create a better understanding of the potential mechanisms that underlie this inverse association. The bulk of the data supporting this association comes from the USA, as evidence for this association is less consistent in many other regions of the world...
September 2012: Urologic Oncology
Cristina Bosetti, Valentina Rosato, Danilo Buniato, Antonella Zambon, Carlo La Vecchia, Giovanni Corrao
OBJECTIVE: To clarify and quantify the effect of thiazolidinediones (TZDs; e.g., pioglitazone, rosiglitazone) on the risk of bladder cancer, other selected cancers, and overall cancer in patients with type 2 diabetes, we performed a systematic review and meta-analysis of observational studies. METHODS: A PubMed/MEDLINE search was conducted for studies published in English up to June 30, 2012. Random-effect models were fitted to estimate summary relative risks (RR)...
2013: Oncologist
Chenwei Wu, William J Aronson, Martha K Terris, Joseph C Presti, Christopher J Kane, Christopher L Amling, Stephen J Freedland
OBJECTIVE: To examine the association between diabetes and metastasis risk after radical prostatectomy (RP) and to determine if race or obesity modifies this relationship. PATIENTS AND METHODS: Patients comprised 2058 US veterans with prostate cancer (PCa) enrolled in the Shared Equal-Access Regional Cancer Hospital (SEARCH) database and treated with RP between 1988 and 2010. The association of diabetes with metastasis risk or secondary treatment rates was examined using Cox proportional hazards, adjusting for preoperative and, separately, clinical and postoperative findings...
June 2013: BJU International
Hongzhou Cai, Zicheng Xu, Ting Xu, Bin Yu, Qing Zou
PURPOSE: Diabetes mellitus is associated with a decreased risk of prostate cancer. However, previous studies examining the associations between diabetes mellitus and prostate cancer prognosis have produced mixed results. Here, we aim to summarize the effect of diabetes mellitus on prostate cancer prognosis. METHODS: We searched the database of PubMed from inception through 31 March 2014 for articles evaluating the effect of diabetes on outcome in prostate cancer patients, and a meta-analysis was conducted...
May 2015: Diabetes/metabolism Research and Reviews
Josephine Kang, Ming-Hui Chen, Yuanye Zhang, Brian J Moran, Daniel E Dosoretz, Michael J Katin, Michelle H Braccioforte, Sharon A Salenius, Anthony V D'Amico
PURPOSE: It has been recently shown that diabetes mellitus (DM) is significantly associated with the likelihood of presenting with high-grade prostate cancer (PCa) or Gleason score (GS) 8 to 10; however, whether this association holds for both Type 1 and 2 DM is unknown. In this study we evaluated whether DM Type 1, 2, or both are associated with high-grade PCa after adjusting for known predictors of high-grade disease. METHODS AND MATERIALS: Between 1991 and 2010, a total of 15,330 men diagnosed with PCa and treated with radiation therapy were analyzed...
March 1, 2012: International Journal of Radiation Oncology, Biology, Physics
Jong Jin Oh, Sung Kyu Hong, Sangchul Lee, Seung June Sohn, Sang Eun Lee
OBJECTIVE: To investigate whether diabetes mellitus (DM) was associated with postoperative outcomes, including prostate-specific antigen doubling time, among men who underwent radical prostatectomy (RP) for clinically localized prostate cancer (PCa). METHODS: Data of 661 patients who underwent radical prostatectomy for node-negative prostate cancer and were followed up for ≥3 years postoperatively at our institution were analyzed. Associations between diabetes mellitus at surgery and outcomes following radical prostatectomy, such as biochemical recurrence-free survival and prostate-specific antigen doubling time, were examined...
February 2013: International Urology and Nephrology
Malte Rieken, Luis A Kluth, Evanguelos Xylinas, Harun Fajkovic, Andreas Becker, Pierre I Karakiewicz, Michael Herman, Yair Lotan, Christian Seitz, Paul Schramek, Mesut Remzi, Wolfgang Loidl, Karl Pummer, Richard K Lee, Talia Faison, Douglas S Scherr, Alexandra Kautzky-Willer, Alexander Bachmann, Ashutosh Tewari, Shahrokh F Shariat
PURPOSE: The impact of diabetes mellitus (DM) and metformin use on biochemical recurrence (BCR) in patients treated with radical prostatectomy (RP) remains controversial. METHODS: We retrospectively evaluated 6,863 patients who underwent RP for clinically localized PC between 2000 and 2011. Univariable and multivariable Cox regression models addressed the association of DM and metformin use with BCR. RESULTS: Overall, 664 patients had a diagnosis of DM from which 287 (43 %) were on metformin and 377 (57 %) were on anti-diabetics other than metformin...
August 2014: World Journal of Urology
Dharam Kaushik, R Jeffrey Karnes, Manuel S Eisenberg, Laureano J Rangel, Rachel E Carlson, Eric J Bergstralh
OBJECTIVE: Recent studies have shown a relative risk reduction in the incidence of prostate cancer in patients taking metformin. However, there are conflicting findings on the effect of metformin on established cases of prostate cancer. In this study we evaluated the effect of metformin on survival and pathologic outcomes in established prostate cancer. MATERIALS AND METHODS: We retrospectively identified 12,052 patients who underwent radical prostatectomy between 1997 and 2010 at Mayo Clinic...
January 2014: Urologic Oncology
Howard S Kim, Joseph C Presti, William J Aronson, Martha K Terris, Christopher J Kane, Christopher L Amling, Stephen J Freedland
PURPOSE: Several studies have examined the association between diabetes mellitus (DM) and prostate cancer (PCa) risk and progression, however nearly all of these studies have compared diabetic versus non-diabetic men. We sought to investigate the role of glycemic control, as measured by HbA1c, on PCa aggressiveness and prognosis in men with DM and PCa from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. METHODS: We identified 247 men in SEARCH with DM and a recorded HbA1c value within the 12 months prior to radical prostatectomy between 1988 and 2009...
October 1, 2010: Prostate
Anna Hitron, Val Adams, Jeff Talbert, Doug Steinke
BACKGROUND: The development of prostate tumors has been linked to co-morbid diabetes mellitus (DM) in several studies, potentially through the stimulation of insulin-like growth factor receptor (IGFR). This study evaluates the effect of anti-diabetic medication use on the development of high grade tumors and time to tumor progression compared to non-diabetics. METHODS: This retrospective, nested case control study identified patients with prostate cancer (PCa) from the Kentucky Medicaid Database...
August 2012: Cancer Epidemiology
Leah Bensimon, Hui Yin, Samy Suissa, Michael N Pollak, Laurent Azoulay
PURPOSE: The aim of this study was to determine whether type 2 diabetes is associated with the incidence of prostate cancer mortality and all-cause mortality. METHODS: This study was conducted by linking four databases from the United Kingdom: the National Cancer Data Repository, the Clinical Practice Research Datalink, the Hospital Episodes Statistics database, and the Office for National Statistics database. The cohort consisted of men newly diagnosed with non-metastatic prostate cancer between 1 April 1998 and 31 December 2009, followed until 1 October 2012...
March 2014: Cancer Causes & Control: CCC
Mathis Grossmann, Gary Wittert
Metabolic disorders such as diabetes, obesity and the metabolic syndrome have been shown to modulate prostate cancer (PCa) risk and aggressiveness in population-based and experimental studies. While associations between these conditions are modest and complex, two consistent findings have emerged. First, there is observational evidence that obesity and associated insulin excess are linked to increased PCa aggressiveness and worse outcomes. Secondly and somewhat paradoxically, long-standing diabetes may be protective against PCa development...
October 2012: Endocrine-related Cancer
Mark A Preston, Anders H Riis, Vera Ehrenstein, Rodney H Breau, Julie L Batista, Aria F Olumi, Lorelei A Mucci, Hans-Olov Adami, Henrik T Sørensen
BACKGROUND: Metformin may decrease prostate cancer (PCa) risk by reducing hyperinsulinemia-associated carcinogenesis or through direct effects on cancer cells. OBJECTIVE: To evaluate the association between metformin use and PCa diagnosis. DESIGN, SETTING, AND PARTICIPANTS: We used the Danish Cancer Registry and the Aarhus University Prescription Database to conduct a nested case-control study among men residing in northern Denmark from 1989 to 2011...
December 2014: European Urology
Aruna V Sarma, James Hotaling, Rodney L Dunn, Patricia A Cleary, Barbara H Braffett, Catherine Kim, Catherine Martin, William Herman, Patricia Gatcomb, Alan M Jacobson, Sarah K Holt, Hunter Wessells
PURPOSE: Previous studies have revealed lower prostate specific antigen concentrations in men with type 2 diabetes, paralleling the reported lower prevalence of prostate cancer in diabetic men. Data are lacking on prostate specific antigen in men with type 1 diabetes whose insulin and obesity profiles differ from those with type 2 diabetes mellitus. In this study we examined the relationship between long-term glycemic control and prostate specific antigen in men with type 1 diabetes mellitus...
March 2015: Journal of Urology
David Margel, David R Urbach, Lorraine L Lipscombe, Chaim M Bell, Girish Kulkarni, Peter C Austin, Neil Fleshner
PURPOSE: To evaluate the association between cumulative duration of metformin use after prostate cancer (PC) diagnosis and all-cause and PC-specific mortality among patients with diabetes. PATIENTS AND METHODS: We used a population-based retrospective cohort design. Data were obtained from several Ontario health care administrative databases. Within a cohort of men older than age 66 years with incident diabetes who subsequently developed PC, we examined the effect of duration of antidiabetic medication exposure after PC diagnosis on all-cause and PC-specific mortality...
September 1, 2013: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Mitchell J Machiela, Sara Lindström, Naomi E Allen, Christopher A Haiman, Demetrius Albanes, Aurelio Barricarte, Sonja I Berndt, H Bas Bueno-de-Mesquita, Stephen Chanock, J Michael Gaziano, Susan M Gapstur, Edward Giovannucci, Brian E Henderson, Eric J Jacobs, Laurence N Kolonel, Vittorio Krogh, Jing Ma, Meir J Stampfer, Victoria L Stevens, Daniel O Stram, Anne Tjønneland, Ruth Travis, Walter C Willett, David J Hunter, Loic Le Marchand, Peter Kraft
Observational studies have found an inverse association between type 2 diabetes (T2D) and prostate cancer (PCa), and genome-wide association studies have found common variants near 3 loci associated with both diseases. The authors examined whether a genetic background that favors T2D is associated with risk of advanced PCa. Data from the National Cancer Institute's Breast and Prostate Cancer Cohort Consortium, a genome-wide association study of 2,782 advanced PCa cases and 4,458 controls, were used to evaluate whether individual single nucleotide polymorphisms or aggregations of these 36 T2D susceptibility loci are associated with PCa...
December 15, 2012: American Journal of Epidemiology
2014-10-27 04:39:35
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"